Randomized, Double-blind, Phase 3 Study Evaluating TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Gastric Cancer Refractory to Standard Treatments
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 09 May 2018
At a glance
- Drugs Tipiracil/trifluridine (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Registrational; Therapeutic Use
- Acronyms TAGS
- Sponsors Taiho Pharmaceutical
- 09 May 2018 According to Taiho Oncology media release, company Announces Positive Topline Results from this trial.
- 09 May 2018 Primary endpoint has been met. (Overall Survival)
- 04 Jan 2018 Status changed from recruiting to active, no longer recruiting.